BMO Capital Maintains Outperform on Sarepta Therapeutics, Maintains $170 Price Target
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Kostas Biliouris maintains an Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) with a $170 price target.
June 18, 2024 | 4:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BMO Capital analyst Kostas Biliouris has reiterated an Outperform rating for Sarepta Therapeutics, maintaining a price target of $170.
The reaffirmation of an Outperform rating and a $170 price target by BMO Capital is a positive signal for investors, suggesting confidence in Sarepta Therapeutics' future performance. This could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100